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Several linkage studies across multiple population groups provide convergent support for a susceptibility locus for
schizophrenia—and, more recently, for bipolar disorder—on chromosome 6q13-q26. We genotyped 192 European-
ancestry and African American (AA) pedigrees with schizophrenia from samples that previously showed linkage
evidence to 6q13-q26, focusing on the MOXD1-STX7-TRARs gene cluster at 6q23.2, which contains a number of
prime candidate genes for schizophrenia. Thirty-one screening single-nucleotide polymorphisms (SNPs) were se-
lected, providing a minimum coverage of at least 1 SNP/20 kb. The association observed with rs4305745 (Pp
) within the TRAR4 (trace amine receptor 4) gene remained significant after correction for multiple testing..0014
Evidence for association was proportionally stronger in the smaller AA sample. We performed database searches
and sequenced genomic DNA in a 30-proband subsample to obtain a high-density map of 23 SNPs spanning 21.6
kb of this gene. Single-SNP analyses and also haplotype analyses revealed that rs4305745 and/or two other poly-
morphisms in perfect linkage disequilibrium (LD) with rs4305745 appear to be the most likely variants underlying
the association of the TRAR4 region with schizophrenia. Comparative genomic analyses further revealed that
rs4305745 and/or the associated polymorphisms in complete LD with rs4305745 could potentially affect gene
expression. Moreover, RT-PCR studies of various human tissues, including brain, confirm that TRAR4 is prefer-
entially expressed in those brain regions that have been implicated in the pathophysiology of schizophrenia. These
data provide strong preliminary evidence that TRAR4 is a candidate gene for schizophrenia; replication is currently
being attempted in additional clinical samples.
Introduction
Schizophrenia is a frequently chronic and devastating
brain disorder that affects ∼1% of the population world-
wide (Jablensky et al. 1992). Typically, it presents in
adolescence or young adulthood and is characterized by
major disruptions of thinking (delusions and/or disor-
ganization), perception (hallucinations), mood, and be-
havior (Gottesman and Shields 1982). Schizophrenia is
strongly familial, with a heritability of ∼80%, but its
etiology is hypothesized to involve both genetic and en-
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vironmental factors (Sanders and Gejman 2001). Re-
cently, encouraging evidence for several genes potentially
involved in the etiology of schizophrenia has been re-
ported—namely, dysbindin (DTNBP1) (Straub et al.
2002; Schwab et al. 2003), neuregulin 1 (NRG1) (Ste-
fansson et al. 2002, 2003; Williams et al. 2003), proline
dehydrogenase (oxidase) 1 (PRODH) (Jacquet et al.
2002; Liu et al. 2002), catechol-O-methyltransferase
(COMT) (Li et al. 2000; Egan et al. 2001; Shifman et
al. 2002), regulator of G-protein signaling 4 (RGS4)
(Chowdari et al. 2002; Morris et al. 2004; Williams et
al. 2004), D-amino-acid oxidase activator (DAOA [pre-
viously called G72]) (Chumakov et al. 2002; Schu-
macher et al. 2004), and D-amino-acid oxidase (DAO)
(Chumakov et al. 2002; Schumacher et al. 2004). Ad-
ditionally, Brzustowicz et al. (2004) reported linkage dis-
equilibrium between C-terminal PDZ domain ligand of
neuronal nitric oxide synthase (CAPON) and schizo-
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phrenia, perhaps related to a previous association signal
at D1S1679, which is ∼25 kb distal to CAPON (Rosa
et al. 2002). Most of the aforementioned genes are po-
sitional candidates with likely involvement in dopa-
minergic or N-methyl D-aspartate (NMDA) brain
mechanisms.
We previously reported linkage of schizophrenia to
chromosome 6q13-q26 (SCZD5 [MIM 603175]) (Cao
et al. 1997), which has accumulated support from a
number of studies (Kaufmann et al. 1998; Martinez et
al. 1999; Bailer et al. 2000; Levinson et al. 2000; Lin-
dholm et al. 2001; Lerer et al. 2003; Lewis et al. 2003).
In the first report of linkage to 6q (Cao et al. 1997),
support for linkage was observed in the region from
D6S301 (located at 111 cM) to D6S305 (located at 170
cM). Linkage to this region was confirmed in subse-
quent studies (Kaufmann et al. 1998; Martinez et al.
1999; Levinson et al. 2000). All the families used in this
study are from three data sets, which we call “NIMH-
IRP” (National Institute of Mental Health Intramural
Research Program), “NIMH-GI” (NIMH Genetics In-
itiative), and “AU/US” (Australia/United States), that
previously have been shown to yield evidence for link-
age to chromosome 6q13-q26 (SCZD5) (Cao et al.
1997; Martinez et al. 1999; Levinson et al. 2000). An
analysis of 12 microsatellite markers in a 50-cM 6q
region was performed by Martinez et al. (1999); non-
parametric affected sibling pair methods yielded P val-
ues of .00018, .00095, and .013 for the NIMH-IRP,
NIMH-GI, and AU/US data sets, respectively. In a Pa-
lestinian/Israeli pedigree sample (Lerer et al. 2003), the
linkage peak with a nonparametric linkage (NPL) score
of 4.61 was at D6S292 (∼137 cM), and the region from
∼131 cM to ∼144 cM contained the 1-NPL decrease
portion of the linkage peak. Furthermore, another
group found evidence for linkage in a Swedish pedigree
to the region from ∼170 cM to ∼180 cM (Lindholm et
al. 2001). Whether these different results are better ex-
plained by the presence of more than one schizophrenia
susceptibility gene in 6q or reflect typical peak varia-
bility in complex disorders (Hauser and Boehnke 1997;
Hsueh et al. 2001) is currently unknown. Recently, bi-
polar disorder was reported to map to 6q, with one
study yielding a maximum LOD score of 2.2 at 113 cM
near D6S1021 (Dick et al. 2003) and another study
reporting a maximum LOD score of 3.56 at ∼124–126
cM near D6S1639 (Middleton et al. 2004), raising the
possibility that a common gene for schizophrenia and
bipolar disorder may be located in 6q.
We were interested in a MOXD1-STX7-TRARs gene
cluster at 6q23.2 (132.8 cM) that harbors prime can-
didates for schizophrenia (fig. 1): MOXD1 (monoox-
ygenase, dopamine-b-hydroxylase-like 1) (Chambers et
al. 1998), STX7 (syntaxin 7) (Wang et al. 1997), and
all known human trace amine receptor (TRAR) genes—
namely, TRAR1, TRAR3, TRAR4, TRAR5, PNR (pu-
tative neurotransmitter receptor gene) (Zeng et al. 1998;
Borowsky et al. 2001; Bunzow et al. 2001; Lee et al.
2001), and three TRAR pseudogenes (TRAR2 , GPR57,
and GPR58 [GPR57 and GPR58 are G-protein–cou-
pled receptor pseudogenes]) (Liu et al. 1998; Borowsky
et al. 2001; Bunzow et al. 2001; Lee et al. 2001).
Trace amines (TAs) are endogenous amine com-
pounds that are chemically similar to classic biogenic
amines like dopamine (DA), norepinephrine, serotonin,
and histamine. Abnormalities that involve the classic
biogenic amines are the basis for biological hypotheses
for a wide variety of disorders, including dystonias, Par-
kinson disease, schizophrenia, drug addiction, and
mood disorders. In mammals, TAs are present at low
levels, with no apparent dedicated synapses, but a
blockage of amine degradation leads to significant ac-
cumulations of TAs, suggesting high synthesis and turn-
over, as reviewed elsewhere (Premont et al. 2001). TAs
in mammals include tyramine (TYR), tryptamine, b-
phenylethylamine (b-PEA), and octopamine (OCT)
(Branchek and Blackburn 2003), and all are synthesized
from amino acid precursors by the aromatic amino acid
decarboxylase.
TAs were thought to be “false transmitters,” which
displace classic biogenic amines from their storage and
act on transporters in a fashion similar to the amphet-
amine (Parker and Cubeddu 1986), but the identifica-
tion of brain receptors specific to TAs indicates that they
also have effects of their own (Borowsky et al. 2001).
This might explain the fact that, although TYR, b-PEA,
OCT, and amphetamine would require the integrity of
vesicular stores of DA if displacement of DA were their
only mechanism of action, they (except OCT) are still
active when DA is depleted (Baud et al. 1985). TRARs
bind amphetamine, MDMA (3,4-methylenedioxymeth-
amphetamine, known as “ecstasy”), and LSD (D-lys-
ergic acid diethylamide) with high affinity. This suggests
a direct link between TRARs and mechanisms of psy-
chosis, because the administration of amphetamine can
induce a schizophrenia-like psychosis (Connell 1958;
Snyder et al. 1967; Angrist et al. 1974; Laruelle and
Abi-Dargham 1999). In addition, psychedelic experi-
ences induced by LSD can have a remarkable similarity
to schizophrenia (Vardy and Kay 1983; Gouzoulis et al.
1994). Furthermore, LSD can induce habituation defi-
cits (the normal decrease in response magnitude to re-
peated stimuli over time) that are similar to those ex-
hibited by patients with schizophrenia (Geyer and Braff
1987; Braff et al. 1992).
MOXD1 is a homologue of dopamine-b-hydroxylase
that is potentially involved in the biosynthesis of nor-
epinephrine from DA (Chambers et al. 1998). Syntaxin
7 (STX7) is a critical component of the synaptic protein
complex SNARE (receptor for soluble N-ethylmaleim-
626 Am. J. Hum. Genet. 75:624–638, 2004
Figure 1 Genomic structure of the 6q23.2 gene cluster and association mapping of the initial screening. The genomic positions are based
on the UCSC July 2003 assembly of the human genome (see the UCSC Genome Bioinformatics Web site). a, The relative position of the 6q23.2
gene cluster to the peak markers from various linkage studies: D6S424 (Cao et al. 1997; Martinez et al. 1999), D6S416 (Cao et al. 1997),
D6S292 (Lerer et al. 2003), and D6S264 (Lindholm et al. 2001). b, Genes in the 6q23.2 gene cluster. c, The log transformation of the FBAT
P value for the 31 SNP markers analyzed in the initial association screening. Each data point of the markers points to its relative position in
the gene cluster shown in panel b. The most significant marker is rs4305745, with a P value of .0014 (see table A5 [online only], for FBAT P
values and other detailed information for all the initially selected markers, and table 1, for the single-marker association results for all the
additional TRAR4 markers examined in the dense mapping effort).
ide-sensitive factor attachment proteins), which is in-
volved in NMDA receptor and dopaminergic receptor
function (Pei et al. 2004); the dysfunction of SNARE
has been suggested in schizophrenia (Honer et al. 2002).
Specifically, syntaxins mediate vesicle fusion in vesicular
transport processes (Teng et al. 2001). We investigated
DNA polymorphisms in the MOXD1-STX7-TRARs
cluster by use of family-based association methods, and
here we present preliminary evidence of association be-
tween TRAR4 and schizophrenia.
Material and Methods
Subjects and Phenotypes
Three samples were studied, which we call the
“NIMH-IRP,” “NIMH-GI,” and “AU/US” collections.
Ascertainment of the NIMH-IRP sample was initially
described by Gershon et al. (1988). The full sample—
from which the present sample of 67 pedigrees was
drawn—was described later (Cao et al. 1997; Gejman
et al. 2001). The collection of the NIMH-GI sample was
described in a report of a genome scan of 71 pedigrees
(Cloninger et al. 1998), and additional NIMH-GI fam-
ilies were subsequently included in the repository-based
data set (see the “Electronic-Database Information” sec-
tion). Of these NIMH-GI pedigrees, 69 were used in the
present analysis and for two previous ones (Cao et al.
1997; Martinez et al. 1999). The AU/US sample was
described initially in a report of a genome scan of 43
pedigrees (Levinson et al. 1998); full or partial trios for
the present study were from 56 of the 71 pedigrees in
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the expanded sample used in linkage fine-mapping stud-
ies (Mowry et al. 2000) and in additional analyses of
this data set (Martinez et al. 1999; Levinson et al. 2000).
For the present study, we genotyped a total of 827 in-
dividuals from 192 families (67 NIMH-IRP families, 69
NIMH-GI families, and 56 AU/US families). Details are
provided in table A1 (online only) and in the “Electronic-
Database Information” section. Schizophrenia and schi-
zoaffective disorder were diagnosed using the criteria of
the DSM-IIIR (American Psychiatric Association 1987).
The institutional review board of the Evanston North-
western Healthcare Research Institute approved this
study.
SNP Selection and Genotyping
SNPs were selected from public databases with the
help of a bioinformatics tool, SNPper (Riva and Kohane
2002), and novel TRAR4 SNPs were identified by direct
sequencing. The DNA samples were genotyped using
one of two methods: (1) template-directed dye-termi-
nator incorporation with fluorescence-polarization de-
tection (FP-TDI) (Chen et al. 1999) or (2) the TaqMan
assay developed by Applied Biosystems. For the FP-TDI
assays, after PCR amplification of genomic DNA, the
AcycloPrime-FP SNP detection kit (PerkinElmer) was
used for post-PCR cleanup and the single-base extension
reaction. We detected FP by use of either an Analyst
fluorescence reader (LJL Biosystems) or a Wallac Victor3
(PerkinElmer), and FP data were converted to genotypes
with the assistance of an automated genotype-calling
spreadsheet (Akula et al. 2002). PCR primers and probes
for the FP-TDI assays were designed using Primer3
(Rozen and Skaletsky 2000). For the TaqMan assays,
the genomic sequence flanking the SNP was submitted
to Applied Biosystems for development of an assay-by-
design. Each unique TaqMan minor-groove–binding
(MGB) allele-specific probe was labeled with either a 5′-
FAM or a 5′-VIC reporter dye. PCR amplification of
genomic DNA was performed in a 384-well plate in an
ABI Prism 7900 or a DNA Engine Tetrad 2 (MJ Re-
search). After PCR, the allele discrimination was per-
formed on an ABI Prism 7900 Sequence Detection Sys-
tem by use of Sequence Detector Software (SDS), version
2.0. Standard genotype calling was converted by a cus-
tomized spreadsheet. Nucleotide sequences for the PCR
primers, the FP-TDI and TaqMan probes, and related
information for each marker can be found in table A2
(online only).
The average completion rate of our experiments was
96%. To empirically check for errors in the genotyping
method, we compared the results for marker rs4305745
from both methods; the difference rate between FP-TDI
and the TaqMan assay was ∼0.25% (data not shown).
We used MERLIN (Multipoint Engine for Rapid Like-
lihood Inference) (Abecasis et al. 2002) (with all the
SNPs at once) to check for Mendelian inconsistencies,
blanked them as described below (sometimes for in-
dividuals and sometimes for the family, when the error
could not be traced to a particular individual), and then
addressed all unlikely recombinants. Genotyping errors
were detected for 0.17% of genotypes (MERLIN) (95
errors/54,611 nonzero genotypes), including 26 Men-
delian inconsistencies (0.047%) and 69 unlikely recom-
binants (0.12%). We did not change genotypes for un-
likely recombinants unless (1) MERLIN estimated a high
probability of an individual genotype error, compared
with other possible errors (see MERLIN documentation
for details), and/or (2) manual rereading of each geno-
type tracing or other raw genotyping output for the fam-
ily/marker in question pinpointed a specific error for a
particular individual. All genotype errors (Mendelian in-
consistencies or specific errors that resulted in unlikely
recombinants) were blanked (zeroed) for the involved
individuals, and, given our high genotyping completion
rate and low genotyping error, we did not perform a
second-pass genotyping procedure for these individuals.
Genotypes were read blind to psychiatric status. We
checked Hardy-Weinberg equilibrium (HWE) for fam
ily founders (at least 200 individuals) for all 55 SNPs.
Three MOXD1 SNPs were found not to be in HWE
(rs2206064, rs1981187, and rs2275394 [although the
HWE P value for rs2206064 did not remain significant
after the number of markers examined for HWE was
taken into account]). The minor-allele frequency of
rs2206064 was only 2%, which might explain the lack
of HWE. The frequencies of homozygotes for both
rs1981187 and rs2275394 were higher than expected
(this was not a bias introduced by cleaning—only a
handful genotypes were blanked, and they were not pri-
marily heterozygous genotypes). We suspected that our
mixed-pedigree sample might have contributed to the
absence of HWE, and, indeed, we found that these
MOXD1 SNPs were all in HWE when the European-
ancestry (EA) founders and the African American (AA)
founders were analyzed separately (data not shown).
Intermarker Linkage Disequilibrium (LD) Analysis
LD between the SNPs was estimated with the program
ldmax from the GOLD (Graphical Overview of Linkage
Disequilibrium) package (Abecasis and Cookson 2000)
by use of the genotypes from unrelated founders. The
program ldmax estimates haplotype frequencies from
genotype data by employing an expectation-maximiza-
tion algorithm (Excoffier and Slatkin 1995). The stan-
dard and normalized Lewontin’s disequilibrium coeffi-
cients (D, D′) are derived. Association significance is
assessed from a x2 distribution with de-(n  1)(n  1)1 2
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grees of freedom, where n1 and n2 are the number of
alleles at each marker locus.
Association Analysis
To detect LD with illness, we used the transmission/
disequilibrium test (TDT), as implemented in the Family-
Based Association Test (FBAT) program, version 1.5
(Laird et al. 2000; Rabinowitz and Laird 2000). The
null hypothesis of interest is the absence of association
in the presence of linkage. We thus employed the em-
pirical-variance estimator (the e flag option in the
FBAT program) to account for SNP-genotype correla-
tions among affected siblings that result from linkage.
The FBAT test statistic uses a score function, Zp
, where Sj is the observed number ofS  E(S )/ Var (S )j j j
transmitted marker alleles, j, to affected offspring, and
E(Sj) and Var(Sj) are the expected and variance values
of Sj under the null hypothesis. Asymptotically, Z is as-
sumed to follow a normal distribution, with a mean and
a variance equal to 0 and 1, respectively. The test statistic
can also be expressed as Z2, which follows a x2 distri-
bution, with 1 df. The FBAT program is able to deal
with the transmission of multilocus haplotypes, even
when phase is unknown and parental genotypes may be
missing. It can use pedigrees as well as nuclear families,
but pedigrees are broken down into all individual nu-
clear families; only informative families (i.e., those con-
tributing to the test statistic) are included. For the anal-
yses of the screening SNPs, alleles and haplotypes were
tested for association if they were present in at least 10
informative families; in our data, this corresponds to not
testing alleles and haplotypes rarer than 3%. This re-
striction, however, was not used when the investigation
was limited to specific subsets of families in the second-
ary analyses. For multilocus association analyses, FBAT
provides global P values, which assess the significance
of transmission distortion for all the tested haplotypes.
In the present analyses, we limited the number of mul-
tilocus systems tested by use of a stepwise procedure and
by restriction of multilocus tests to combinations that
included the SNP with highest single Z score value, as
further detailed in the “Results” section below. For the
FBAT analyses, we assumed an additive model for each
SNP, and only one affection status model was used (af-
fected subjects had schizophrenia or schizoaffective dis-
order). The additive model is expected to perform well
even when the true model is nonadditive.
Linkage Analysis
Model-free linkage analyses with the MOXD1-STX7-
TRARs gene cluster were performed using the LOD
score test from the affecteds-only sharing method (Kong
and Cox 1997), as implemented in the MERLIN pro-
gram (Abecasis et al. 2002). The likelihood of the ob-
served marker information among affected relatives is
maximized as a function of the marker-allele–sharing
parameter and is compared, using a likelihood-ratio test,
with the likelihood of the marker data under the null
hypothesis of no linkage. The resulting distribution of
the allele-sharing test (T) is x2, with 1 df, and the statistic
can also be reported as a LOD score of .T/2 ln (10)
We performed additional analyses, by race, to account
for putative genetic and/or allelic heterogeneity within
our family samples. Association and linkage tests were
evaluated separately in AA and EA families.
Mutation Detection
Sequencing of TRAR4 was performed on an ABI 3100
Genetic Analyzer. Purified PCR products from various
amplicons of relevant genomic DNA fragments were
used as templates in sequencing reactions with the chem-
istry of BigDye 3.1 (Applied Biosystems). PCR primers
were designed by Primer3 (Rozen and Skaletsky 2000)
and were also used as sequencing primers for forward
and reverse sequencing. The primer sequences and prod-
uct sizes are given in table A3 (online only). We used
the software SeqScape, version 2.1 (Applied Biosystems),
to assist in mutation detection, and we visually verified
each mutation. The reference sequence of TRAR4 used
in the analysis was from the University of California–
Santa Cruz (UCSC) human genome draft, July 2003
freeze (see the UCSC Genome Bioinformatics Web site).
For the nonhuman primates, DNAs were extracted
from peripheral blood samples of two different chimpan-
zees (PTR-S109 and PTR-S286) from West Africa and
from tissue samples of two different lowland gorillas
(GGO-S110 and GGO-S249). The forward primer for
amplicon 1 and the reverse primer for amplicon 7 were
used to PCR-amplify the entire DNA segment by standard
methods, with an annealing temperature of 60C. This
product was then sequenced bidirectionally with the seven
primer pairs that are detailed in table A3 (online only).
PCR products were confirmed by 1.5% agarose gel elec-
trophoresis and were purified using MicroSpin Columns
(Amersham Biosciences). The purified PCR products were
sequenced using the BigDye Terminator Cycle Sequencing
Kit (Applied Biosystems) on an ABI Prism 377/3100 DNA
sequencer. Sequence data were assembled by the Phred/
Phrap program (Ewing et al. 1998) and also were checked
manually using the Consed program (Gordon et al. 1998).
Sequence data with reads for both strands and/or with
high quality (130 quality value) were used and deposit-
ed into the DDBJ/EMBL/GenBank International Nucleo-
tide Sequence Database (accession numbers AB180397–
AB180400).
RT-PCR and Real-Time PCR
Total mRNAs from various brain tissues were pur-
chased from either BD Biosciences or Ambion. Gene ex-
pression of TRAR4 was first confirmed with general RT-
Duan et al.: TRAR4 Association with Schizophrenia 629
Table 1
Single-Marker Association Results for TRAR4
TRAR4
MARKER
dbSNP
ACCESSION
NO.a
DISTANCE
(bp)b
POSITION
(bp)c
NUCLEOTIDE AT
ASSOCIATED
ALLELE
ALLELE
FREQUENCY
TRANSMISSIONS
Z PAllele 1 Allele 2 Observed Expected Variance
1 rs2840837 1,753 132,864,153 A G 1 .281 95 93.60 46.41 .21 .84
2 rs1361280 1,196 132,865,906 A G 1 .549 186 175.93 72.91 1.18 .24
3 rs4473885 813 132,867,102 C T 1 .548 205 193.60 82.47 1.26 .21
4 rs4085406 3,403 132,867,915 A G 1 .545 189 178.60 80.13 1.16 .25
5 rs6907909 437 132,871,318 A G 1 .636 193 181.03 80.69 1.33 .18
6 ss28447860 385 132,871,755 C G 1 .848 143 132.20 37.38 1.77 .08
7 ss28447862 383 132,872,140 T C 2 .009 8 6.50 3.25 .83 .41
8 ss28447876 25 132,872,523 G A 1 .992 5 4.17 .36 1.39 .17
9 ss28447863 165 132,872,548 A G 2 .008 10 8.17 3.36 1.00 .32
10 ss28447865 110 132,872,713 C T 2 .030 20 17.63 21.73 .51 .61
11 rs8192624 79 132,872,823 A G 2 .933 86 83.12 20.67 .63 .53
12 rs8192625d 104 132,872,902 A G 2 .912 101 91.53 21.15 2.06 .0396
13 ss28447866 70 132,873,006 G A 1 .989 12 9.30 2.69 1.65 .10
14 rs7772821 434 132,873,076 G T 1 .264 102 96.30 45.90 .84 .40
15 ss28447871 772 132,873,510 G A 2 .698 185 179.67 48.99 .76 .45
16 rs4305745d 716 132,874,282 G A 2 .526 168 143.42 59.01 3.20 .0014
17 rs7745308 819 132,874,998 T G 2 .071 30 26.87 16.66 .77 .44
18 rs6912930 1,663 132,875,817 A C 1 .390 124 119.78 60.11 .54 .59
19 rs6903874 948 132,877,480 T C 1 .757 204 180.57 60.40 3.02 .0026
20 rs7765655 1,541 132,878,428 G A 1 .245 73 71.65 39.31 .22 .83
21 rs6937506 3,016 132,879,969 G A 1 .736 199 177.07 61.65 2.79 .0052
22 rs4129284 2,772 132,882,985 C T 1 .413 140 131.98 62.72 1.01 .31
23 rs9321354 NA 132,885,757 A C 1 .165 88 83.43 37.66 .74 .46
a Previously known SNPs are indicated by an rs number; novel SNPs are indicated by an NCBI Assay ID number (ss number) that we obtained
(data to be released in the next build of dbSNP).
b Distance is the number of bp to the next SNP. NA p not applicable.
c Position in bp was derived from UCSC July 2003 freeze of chromosome 6 (see the UCSC Genome Bioinformatics Web site).
d TRAR4 screening SNPs.
PCR with primer pairs used previously for amplification
of segment 4 of TRAR4 (table A3 [online only]). In brief,
total mRNA was reverse-transcribed with TaqMan Re-
verse Transcription Reagents (Applied Biosystems), and
the synthesized first-strand cDNAs were then used as
templates to amplify TRAR4 with HotStarTaq poly-
merase (Qiagen). b-actin was used as an internal control
in the RT-PCR.
Reverse-transcribed cDNAs were also used in real-
time PCR on an ABI Prism 7900 Sequence Detection
System, in accordance with the manufacturer’s protocol.
The TaqMan MGB probes and PCR primer pairs for
the gene-expression assay of TRAR4, GAPD, (glycer-
aldehyde-3-phosphate dehydrogenase), and/or TRAR1
were purchased as an Assay-On-Demand from Applied
Biosystems. The relative gene expression in different
brain tissues was normalized to GAPD expression by
use of the standard-curve method, as described by Ap-
plied Biosystems.
Bioinformatics Tools for Prediction of Functional Effects
of Genetic Polymorphisms
We used SIFT and PolyPhen to predict the potential
functional effect of missense polymorphisms (Ramensky
et al. 2002; Ng and Henikoff 2003). We used VISTA,
which defines the conserved region among genomic se-
quences from different species (Couronne et al. 2003),
to predict the potential regulatory sequences.
Results
We have studied 192 families with previous evidence of
linkage. Of the 33 SNPs initially selected for study, 31
were accepted for analysis in the screening experiment,
since 2 of the MOXD1 SNPs, rs2206064 and rs7751860,
had minor-allele frequencies resulting in !3% informative
families. The screening SNPs spanned ∼500 kb of the
MOXD1-STX7-TRARs gene cluster, which contains a
prime set of positional and pathophysiological candidates
for schizophrenia susceptibility. We selected at least one
common SNP for each gene, with a minimum coverage
of 1 SNP/20 kb (the screening set of SNPs). Linkage
analyses confirmed the presence of excess allele sharing
in this region with individual SNPs from the MOXD1-
STX7-TRARs gene cluster. Nine SNPs showed linkage P
values !.05 (table A4 [online only]), with the most sig-
nificant one being rs6937506 (TRAR4), with a LOD score
of 1.76 ( ).Pp .002
Association results are presented in table 1 and can
also be seen in table A5 (online only). Of 31 screening
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Table 2
Coding SNPs Captured by Resequencing TRAR4 in 30 Probands with Schizophrenia (14 AA and 16 EA Individuals)
dbSNP
ACCESSION NO.a
POSITION
(bp)b SNPc
AMINO
ACID
CHANGE
TYPE OF
CHANGE FUNCTIONd
LOCATION
IN PROTEINe
MINOR-ALLELE
FREQUENCY
Average EAf AAg
rs8192622 132,872,108 C78T Pro26Pro Synonymous NA Extracellular .05 .09 .00
ss28447862 132,872,140 T110C Ile37Thr Conservative Tolerated TMD 1 .03 .00 .07
ss28447876 132,872,523 G493A Gly165Ser Nonconservative Tolerated TMD 4 .02 .00 .04
ss28447863 132,872,548 A518G Tyr173Cys Nonconservative Damaging Extracellular .03 .00 .07
ss28447864 132,872,660 C630G Thr210Thr Synonymous NA TMD 5 .03 .03 .04
ss28447865 132,872,713 C683T Ala228Val Conservative Damaging Cytoplasmic .10 .00 .21
ss28447867 132,872,774 A744G Arg248Arg Synonymous NA Cytoplasmic .02 .00 .04
rs8192624 132,872,823 G793A Val265Ile Conservative Tolerated TMD 6 .10 .16 .04
rs8192625 132,872,902 G872A Cys291Tyr Nonconservative Tolerated TMD 7 .13 .16 .11
ss28447866 132,873,006 G976A Val326Ile Conservative Tolerated Cytoplasmic .03 .00 .07
a Previously known SNPs are indicated by an rs number; novel SNPs are indicated by an NCBI Assay ID number (ss number) that
we obtained (data to be released in the next build of dbSNP).
b Position in bp was derived from the UCSC July 2003 freeze of chromosome 6 (see the UCSC Genome Bioinformatics Web site).
c SNPs were named according to their relative position to the first letter of start codon ATG and with the first base as the major
allele.
d Function determined by SIFT. NA p not applicable.
e The position in the protein was predicted on the basis of 7-transmembrane GPCR structures, as depicted in the GPCR database
(see GPCRDB Web site). TMD p transmembrane domain.
f EA p European ancestry.
g AA p African American.
SNPs, 4 SNPs spanning 106 kb, 2 located in TRAR4
and 1 each in STX7 and GPR57, yielded a P value !.05.
The most significant one, rs4305745, was found in
TRAR4 ( ) (fig. 1c). This SNP was the onlyPp .0014
one that remained significant after Bonferroni correc-
tion for 31 tests (it should be noted that the question
of whether Bonferroni corrections are appropriate or
overly conservative is open to different interpretations;
however, given that LD is likely to be present over short
physical distances, the tests cannot be considered in-
dependent). The SNP rs4305745 is located 1,214 bp
downstream from the stop codon of TRAR4. We con-
centrated further laboratory efforts on TRAR4. We
aimed for a high-density map of 11 SNP/2 kb by search-
ing public SNP databases and sequencing genomic
DNA. We sequenced the TRAR4 gene (∼1 kb of the 5′
region, the 1,038-bp CDS (coding DNA sequence), and
∼1.5 kb of the 3′ UTR, which spans rs4305745) in 30
probands selected from the NIMH-GI families: 16 EA
families and 14 AA families. We found 10 coding var-
iants (26 total variants [table 2 and online-only table
A6]) by sequencing TRAR4. Three of these variants had
previously been found in 96 healthy EA individuals
(Freudenberg-Hua et al. 2003). Of the seven novel var-
iants, five are missense and are present only in AA in-
dividuals, as shown in table 2. From this combined
bioinformatics and sequencing effort, 20 SNPs spanning
21.6 kb of the TRAR4 gene (11 SNP/2 kb) were iden-
tified for genotyping. Two additional markers 3′ to
rs4305745 showed association with schizophrenia in
the whole sample (table 1 and online-only table A7):
rs6903874 ( ) and rs6937506 ( ).Pp .0026 Pp .0052
Two other additional markers (ss28447873 [an inser-
tion/deletion polymorphism] and rs7452939) were
found to be in perfect LD with rs4305745 (they span
53 bp) and, hence, were also associated with illness to
the same degree as rs4305745.
Although similar association trends were observed in
EA and AA individuals, table A7 (online only) shows
that the evidence for association was proportionally
stronger in the AA sample. The evidence for association
with rs4305745 and rs6937506 was significant in both
samples ( in the AA sample and inPp .035 Pp .015
the EA sample for rs4305745; in the AA sam-Pp .025
ple and in the EA sample for rs6937506).Pp .035
However, a cluster of three SNPs in the promoter region
of TRAR4 yielded significant association in the AA sam-
ple—rs4473885 ( ), rs4085406 ( ),Pp .032 Pp .047
and rs6907909 ( )—but not in the EA samplePp .019
(table A7 [online only]). These differences raise the pos-
sibility of allelic heterogeneity specific to the AA pop-
ulation. All new missense mutations detected by se-
quencing were also exclusive to the AA sample (table
2). Two mutations, A518G (Tyr173Cys) and C683T
(Ala228Val), were predicted by either PolyPhen or SIFT
(Ramensky et al. 2002; Couronne et al. 2003; Ng and
Henikoff 2003) to be nonconservative (table 2). How-
ever, after genotyping the whole sample, we noted that
none of the newly found missense SNPs cosegregated
with disease in a specific manner (data not shown). Fur-
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Figure 2 Pairwise LD in 192 founders for the TRAR4 region. a, Relative physical position of 23 markers in the TRAR4 region (shown
in table 1). The SNPs ss28447862, ss28447876, ss28447865, rs8192624, and ss28447866 were excluded in the following LD measurements
because of their low minor-allele frequencies. b, LD pattern in AA subjects (left panel) and EA subjects (right panel). The graph was generated
by GOLD (Abecasis and Cookson 2000). In each LD pattern, the D′ values (upper left diagonal) and the P values (lower right diagonal,
converted to log P values) are calculated from the program ldmax of the GOLD package (Abecasis and Cookson 2000).
thermore, all the missense variants, except for A518G
(Tyr173Cys), were also found in a set of 48 AA subjects
from the Coriell Human Variation AA DNA panel (table
A8 [online only]). Additionally, some of these missense
variants were homozygous in some control individuals.
It is interesting to note that the ratio of missense to
synonymous mutations (9:3) is close to what is pre-
dicted under neutral expectations (i.e., a pseudogene
that has an expected ratio close to 4:1). Indeed, in the
gorilla, TRAR4 has already become a pseudogene (with
a nonsense mutation at codon 15: Tyr in chimpanzee
and human and STOP in gorilla), although the human
and chimpanzee TRAR4 versions have not yet become
pseudogenes.
The TRAR4 region was found to have two LD blocks,
which are depicted in figure 2. The SNP rs4305745
(marker 16 in fig. 2) is in the LD block constituted by
3′-flanking SNPs. The pattern suggests that association
for TRAR4 originates from rs4305745. None of the 5′-
flanking SNPs are in LD with rs4305745, which instead
is in strong LD with markers 19 (rs6903874) and 21
(rs6937506) from the 3′ LD block (and also shows a
trend with marker 12 [rs8192625]). The LD pattern
generated from the 31 initial screening markers indi-
cated that the whole region of the MOXD1-STX7-
TRARs gene cluster is separated into four major strong-
LD blocks, whereas the TRAR4 region represented by
rs4305745 is not in strong LD with any of the major
LD blocks (data not shown).
We conducted haplotype association analyses with all
TRAR4 two-locus systems ( , after exclusion ofnp 17
5 markers with minor-allele frequencies !3%) derived
from rs4305745, which was chosen as the anchor since
it had the most significant single-locus association
( ). For each two-locus system, we derived thePp .0014
global x2 value by use of only those haplotypes with
frequencies 13% (table A9 [online only]). All 17 of these
two-locus systems exhibited P values !.05 (not cor-
rected by multiple testing), and all harbored the “A”
allele of rs4305745. None of the two-locus systems
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Figure 3 Expression pattern of TRAR4 in human tissues. a,
TRAR4 expression pattern in various human brain regions. Lane 1 is
a 100-bp molecular weight standard ladder (Promega). Lanes 2–13
are human brain, human fetal brain, cerebellum, fetal liver, placental,
spinal cord, control (no reverse transcriptase added), basal ganglia,
frontal cortex, substantia nigra, amygdala, and hippocampus. RT-PCR
products from total RNAs are displayed in the photograph of the
ethidium bromide–stained agarose gel; b-actin was used as internal
control. b, Quantitative real-time PCR determined the relative abun-
dance of the TRAR4 transcript in various human brain regions. c,
Comparison of gene expression of TRAR4 with TRAR1. Samples S1–
S6 in panels b and c are basal ganglia, frontal cortex, substantia nigra,
amygdala, hippocampus, and cerebellum.
showed association stronger than that of rs4305745
alone (table A9 [online only]), and the same results were
obtained with up to five multilocus systems, with each
haplotype system extended stepwise to contain the most
significant previous smaller haplotype (data not shown).
This suggests that rs4305745 and/or the other two
nearby polymorphisms, ss28447873 and rs7452939, in
perfect LD (further confirmed by genotyping the whole
sample) with rs4305745 (table A6 [online only]) are the
most likely mutations underlying the association of the
TRAR4 region with schizophrenia susceptibility.
To explore the possible functional effects of associ-
ated SNPs and their haplotypes, we first defined the
conserved noncoding sequence (considered as a poten-
tial functional region) by comparative genomic analysis
of TRAR4 genomic sequences of human, mouse, and
rat by use of VISTA (Couronne et al. 2003). The cluster
of three polymorphisms (rs4305745, ss28447873, and
rs7452939—all equally implicated as candidates by the
association analysis) that exhibit the most significant
association is very close to two conserved regions right
after the stop codon (sequence identity 170% among
human, mouse, and rat genomes). The sequence identity
immediately around this SNP (rs4305745) is ∼50% (fig.
A1 [online only]), suggesting that this SNP and/or other
polymorphisms in perfect LD with rs4305745 may ul-
timately affect gene expression, a hypothesis we are cur-
rently testing. RT-PCR from various brain tissues also
confirmed that rs4305745 was flanked by the 3′ UTR
of TRAR4 (data not shown), suggesting that rs4305745
or one of its haplotypes may affect gene expression at
the posttranscriptional level. Another significant SNP,
rs6903874, is also within a conserved region (fig. A1
[online only]), and it is possible that this SNP and/or
other SNPs nearby might be functional, although this
SNP is much farther than rs4305745 from the stop co-
don of TRAR4.
A comprehensive gene-expression analysis of TRAR4
will help to elucidate its potential functional roles in the
pathophysiology and pharmacology of schizophrenia.
We investigated TRAR4 expression in various human
tissues by RT-PCR and found that TRAR4 was ex-
pressed at low abundance in various human brain tis-
sues as well as in human fetal liver but not in the cer-
ebellum or placenta (fig. 3a). A quantitative real-time
PCR, shown in figure 3b, further revealed that TRAR4
has comparable levels of expression in basal ganglia,
frontal cortex, substantia nigra, amygdala, and hippo-
campus, with the highest expression in hippocampus
and the lowest expression in basal ganglia. These results
are consistent with a previous expression study that in-
cluded TRAR4 (Borowsky et al. 2001). These regions
have been implicated in the pathophysiology and phar-
macology of schizophrenia (Grossberg 2000; Freedman
2003). The tissue distribution of TRAR4 gene expres-
sion is similar to that of the only well-characterized
TRAR, TRAR1 (Borowsky et al. 2001; Bunzow et al.
2001). However, further comparison of gene expression
of TRAR4 and TRAR1 indicated that TRAR4 is, over-
all, more abundant than TRAR1, particularly in basal
ganglia (∼14-fold), frontal cortex (∼21-fold), and sub-
stantia nigria (∼14-fold) (fig. 3c), which suggests that
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TRAR4 may play a more important role than TRAR1
in those regions.
Discussion
TA receptor genes have been proposed as candidate
genes for schizophrenia on the basis of highly provoc-
ative pathophysiological evidence (Boulton 1980; Pre-
mont et al. 2001; Branchek and Blackburn 2003) as well
as linkage mapping data (Cao et al. 1997). Here, we
present preliminary evidence that TRAR4, a gene that
belongs to the TRAR family, contributes to susceptibility
to schizophrenia in three data sets, with evidence of ge-
netic linkage to 6q. Furthermore, the TRARs gene cluster
at chromosome 6q23 is contained within a wide area of
linkage detected in several other clinical samples (Bailer
et al. 2000; Levinson et al. 2000; Lindholm et al. 2001;
Lerer et al. 2003; Lewis et al. 2003). The linkage ev-
idence for schizophrenia in 6q is not population spe-
cific—it has been gathered from multiple population
groups: AA individuals, EA individuals, and Jews and
Arabs from Israel. However, the evidence for association
of TRAR4 in our samples, although present in both EA
and AA individuals, appears higher in AA subjects.
The most significantly associated SNPs within
TRAR4 are located in the 3′ UTR of TRAR4, and these
polymorphisms may affect the gene expression at the
posttranscriptional level. There are several possible
mechanisms by which TRAR4 could contribute to the
pathogenesis of schizophrenia. First, the to-be-deter-
mined ligand(s) of TRAR4 may be neurotransmitter(s)
specifically implicated—by a new signaling pathway—in
schizophrenia. Second, TRAR4 may be activated strongly
by b-PEA, an endogenous chemical analogue of am-
phetamine—or perhaps by amphetamine itself. It has
been documented that amphetamine can produce a par-
anoid schizophrenia syndrome in humans by inducing
DA release in the striatum, and the DA release induced
by amphetamine (or b-PEA) is increased in patients with
schizophrenia (Laruelle et al. 2003). Pharmacological
profiling has shown that b-PEA and amphetamine can
directly activate TRAR1 (Borowsky et al. 2001; Bunzow
et al. 2001). Finally, TRAR4 may crosstalk with the
COMT system, which has been implicated in the path-
ogenesis and etiology of schizophrenia (Li et al. 2000;
Egan et al. 2001; Shifman et al. 2002). It has been shown
that rat TRAR1 can be activated with higher potency
and efficacy by 3-methyltyramine, a major metabolite of
DA produced by COMT, than by the precursor catecho-
lamines (Bunzow et al. 2001). If TRAR4 were shown to
act like TRAR1 in this regard, some “inactive” catecho-
lamine metabolites might act as endogenous agonists of
TRAR4, which could predispose to psychosis. Moreover,
we have shown that TRAR4 is more abundant than
TRAR1 (fig. 3), which suggests that TRAR4 may play a
more important role in areas of the brain that are relevant
to the dopaminergic system. It can be seen that the plau-
sible contributions of TRAR4 to schizophrenia suscep-
tibility are closely related to the DA hypothesis of schizo-
phrenia, a major hypothesis that has been intensively
researched over the past 50 years. Given the increased
understanding about the interactions of the DA system
with the glutamate system in the pathogenesis of schizo-
phrenia (Laruelle et al. 2003), our finding about TRAR4
may prompt new investigations of the interactions among
these neurotransmitter systems.
Regulatory sequence disruption can affect protein ex-
pression and cause disease (Mitchison 2001). The as-
sociated SNPs in the 3′ UTR of TRAR4 may contribute
to the susceptibility for schizophrenia by affecting the
gene expression at the posttranscriptional level. Our RT-
PCR experiment indicated that the TRAR4 3′ UTR
spanned the most associated SNP, rs4305745; therefore,
it is possible that TRAR4 gene expression was affected
at the posttranscriptional level by these 3′ UTR SNPs
(rs4305745 and/or ss28447873 and rs7452939 [two
SNPs in perfect LD with rs4305745]). The chimpanzee
and gorilla sequencing results indicated that the ancestral
allele for rs4305745 is A (table A6 [online only]). Because
of the perfect LD among rs4305745, ss28447873, and
rs7452939, the associated allele A of rs4305745 actual-
ly represents a human haplotype of A-A-A, spanning
rs4305745, ss28447873, and rs7452939 (fig. A1c [online
only]). (Also note that the ancestral haplotype appears
to be A-A-G, as seen in table A6 [online only].) It is
interesting that the predicted TRAR4 mRNA structure
exhibited a significant change for the overtransmitted
haplotype A-A-A, compared with haplotype G-del-G; the
same structure change can be generated by allele A of
rs4305745 alone (data not shown), suggesting that
rs4305745 is most likely the causative SNP.
We have found that the mutation rate in the coding
region for TRAR4 (1 mutation/100 bp) is well above
the average (1 mutation/346 bp) (Cargill et al. 1999).
In addition, there are more missense mutations in
TRAR4 than synonymous mutations (nine vs. three)
(table 2 and online-only table A8), suggesting that
TRAR4 may be becoming a pseudogene. However, an
expressed pseudogene sometimes regulates the mRNA
stability of a homologous gene (Hirotsune et al. 2003).
We did not find evidence of association with schizo-
phrenia for missense SNPs; however, some missense mu-
tations—particularly A518G (Tyr173Cys)—may be
pharmacologically important. A518G is located in the
putative extracellular domain of the receptor and,
hence, may affect ligand binding (table 2). Besides the
changes in protein structure, these missense mutations
may also alter the gene expression by affecting mRNA
folding structures, as described for dopamine D2 re-
ceptor (DRD2) (Duan et al. 2003). Actually, A518G
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was predicted to have a remarkable effect on TRAR4
mRNA folding, as predicted in silico by Mfold (Zuker
et al. 1999) (data not shown). It is also notable that
this missense SNP and several others were only found
in AA subjects, and 173Cys was only detected in AA
probands with schizophrenia. It will be important to
examine the functional effects of some of these missense
SNPs and to test the association with schizophrenia in
additional samples.
Molecular genetics studies of schizophrenia have
found several replicated linkages to various chromo-
somal regions (see review by Owen et al. [2004]), and
association studies have recently pointed to several
genes at some of those linkage regions with independent
confirmations, including NRG1 at 8p21-p12 (Stefans-
son et al. 2002, 2003; Williams et al. 2003), DTNBP1
at 6p22.3 (Straub et al. 2002; Schwab et al. 2003),
COMT at 22q11.21 (Li et al. 2000; Egan et al. 2001;
Shifman et al. 2002), RGS4 at 1q23.3 (Chowdari et al.
2002; Morris et al. 2004; Williams et al. 2004), and
DAOA at 13q33.2 (Chumakov et al. 2002; Schumacher
et al. 2004). Although nonreplications have been re-
ported, it would be extremely unlikely that all the afore-
mentioned results will end as false positives. We now
propose that TRAR4 is also a susceptibility gene for
schizophrenia. There are also two other weak associa-
tion peaks at the MOXD1-STX7-TRARs gene cluster,
in addition to the TRAR4 peak shown in figure 1: one
is in STX7 and the other is in the pseudogene, GPR5.
Therefore, we cannot exclude the possibility that those
loci may also contribute to susceptibility for schizo-
phrenia. The identification of TRAR4 as a susceptibility
gene for schizophrenia, which is consistent with human
and animal models of toxic psychosis and is in agree-
ment with the expression pattern of TRAR4 (expressed
in frontal cortex, amygdala, and hippocampus), appears
to substantiate the dopaminergic hypothesis of schizo-
phrenia, but the exact mechanisms of disease mediated
by TRAR4 remain to be elucidated. The two reports
suggesting linkage of the same 6q chromosomal area to
bipolar disorder raise the possibility that TRAR4 might
be involved in the pathophysiology of both schizophre-
nia and bipolar disorder, and there is a precedent for a
gene potentially involved in both disorders (Chumakov
et al. 2002; Hattori et al. 2003; Chen et al. 2004; Schu-
macher et al. 2004). We would like to note a couple of
caveats: first, our combined sample has a rather modest
size in the context of complex genetics, and, second,
additional gene(s) in the region might account for our
association signal. However, although it is certainly true
that gene-prediction programs have their limitations
and different methods sometimes produce different re-
sults, at least one of them has been able to pick up all
the TRARs genes and pseudogenes we know about (see
the UCSC Genome Bioinformatics Web site [July 2003
freeze]). Although it is possible that gene-prediction
programs have missed a G-protein–coupled receptor
(GPCR) pseudogene, there is little chance they have
missed an actual GPCR gene in this cluster since the
GPCR motif is so robust. Other non-GPCR genes, how-
ever, might have been missed. Although the identifica-
tion of TRAR4 as a susceptibility gene for schizophrenia
is encouraging, it is important that our observations
should be considered as preliminary until replication has
been completed in additional samples.
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